Total Payments
$105,808
2023 Payments
$71.75
Companies
9
Transactions
72
Medicare Patients
660
Medicare Billing
$77,497
Payment Breakdown by Category
Consulting$80,407 (76.0%)
Research$12,970 (12.3%)
Travel$11,509 (10.9%)
Food & Beverage$921.96 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $80,407 | 30 | 76.0% |
| Unspecified | $12,970 | 16 | 12.3% |
| Travel and Lodging | $11,509 | 13 | 10.9% |
| Food and Beverage | $921.96 | 13 | 0.9% |
Payments by Type
General
$92,838
56 transactions
Research
$12,970
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $61,389 | 37 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $23,250 | 13 | $0 (2021) |
| SANOFI US SERVICES INC. | $9,646 | 13 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $5,625 | 1 | $0 (2021) |
| PFIZER INC. | $5,400 | 2 | $0 (2022) |
| AstraZeneca AB | $247.75 | 3 | $0 (2017) |
| Novo Nordisk Inc | $118.34 | 1 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $71.75 | 1 | $0 (2023) |
| Eli Lilly and Company | $60.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $71.75 | 1 | Regeneron Pharmaceuticals, Inc. ($71.75) |
| 2022 | $800.00 | 1 | PFIZER INC. ($800.00) |
| 2021 | $10,725 | 3 | Novartis Pharmaceuticals Corporation ($5,625) |
| 2020 | $4,944 | 10 | SANOFI-AVENTIS U.S. LLC ($3,694) |
| 2019 | $5,401 | 9 | SANOFI-AVENTIS U.S. LLC ($3,651) |
| 2018 | $58,141 | 29 | SANOFI-AVENTIS U.S. LLC ($50,346) |
| 2017 | $25,725 | 19 | AstraZeneca Pharmaceuticals LP ($13,500) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/27/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $71.75 | General |
| 12/19/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 12/10/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| 03/17/2021 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | — | In-kind items and services | $5,625.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH INCLISARIN RESEARCH • Category: CARDIOVASCULAR | ||||||
| 01/29/2021 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/28/2020 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/29/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $1,602.86 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 03/28/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $423.16 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 03/28/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $423.16 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 03/28/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $423.16 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 03/28/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $402.00 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 03/03/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $25.20 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 02/14/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $227.14 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 02/14/2020 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | — | In-kind items and services | $167.37 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: Cardiology/Vascular Diseases | ||||||
| 01/16/2020 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/17/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $1,110.00 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 12/12/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $889.11 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 11/04/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $999.00 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 10/31/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $167.37 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 10/31/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $167.37 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 10/31/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $159.00 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 10/31/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | — | In-kind items and services | $159.00 | Research |
| Study: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab • Category: CARDIOVASCULAR | ||||||
| 08/15/2019 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/22/2019 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/11/2018 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Consulting Fee | Cash or cash equivalent | $3,267.00 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab | SANOFI-AVENTIS U.S. LLC | $7,345 | 15 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH INCLISARIN RESEARCH | Novartis Pharmaceuticals Corporation | $5,625 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 155 | 213 | $63,609 | $16,667 |
| 2022 | 9 | 192 | 254 | $73,012 | $21,158 |
| 2021 | 5 | 140 | 193 | $65,677 | $19,039 |
| 2020 | 5 | 173 | 206 | $69,809 | $20,632 |
Total Patients
660
Total Services
866
Medicare Billing
$77,497
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 73 | $21,681 | $6,057 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 43 | $21,285 | $5,250 | 24.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 36 | $7,560 | $2,136 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 33 | $8,118 | $1,753 | 21.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $3,707 | $1,072 | 28.9% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 17 | 17 | $1,258 | $399.45 | 31.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 82 | $24,354 | $6,532 | 26.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 33 | $16,335 | $4,915 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 37 | $9,102 | $2,676 | 29.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 20 | $6,740 | $2,088 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 13 | $4,537 | $1,454 | 32.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 21 | $4,410 | $1,119 | 25.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $2,882 | $893.10 | 31.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 11 | $2,728 | $776.38 | 28.5% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Office | 2022 | 24 | 26 | $1,924 | $704.71 | 36.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 56 | 56 | $27,720 | $8,679 | 31.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 46 | 98 | $29,106 | $7,917 | 27.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 16 | $3,936 | $1,023 | 26.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 12 | $3,144 | $994.56 | 31.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 11 | $1,771 | $426.32 | 24.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 82 | 83 | $41,085 | $13,239 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 41 | $12,177 | $3,373 | 27.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 28 | 41 | $8,610 | $2,327 | 27.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 25 | $6,150 | $1,167 | 19.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 16 | $1,787 | $526.60 | 29.5% |
About Vera Bittner
Vera Bittner is a Cardiovascular Disease healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699720151.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Vera Bittner has received a total of $105,808 in payments from pharmaceutical and medical device companies, with $71.75 received in 2023. These payments were reported across 72 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($80,407).
As a Medicare-enrolled provider, Bittner has provided services to 660 Medicare beneficiaries, totaling 866 services with total Medicare billing of $77,497. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Birmingham, AL
- Active Since 05/23/2006
- Last Updated 06/29/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1699720151
Products in Payments
- PRALUENT (Drug) $61,830
- EPANOVA (Drug) $23,498
- LEQVIO (Drug) $5,625
- NO PRODUCT DISCUSSED (Drug) $5,510
- PRALUENT (Biological) $3,694
- Victoza (Drug) $118.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Birmingham
Dr. Anil Rajendra, M.d, M.D
Cardiovascular Disease — Payments: $457,890
Cardiovascular Disease $457,890
Robert Bourge, Md, MD
Cardiovascular Disease — Payments: $433,960
Cardiovascular Disease $433,960
Vikram Arora, Md, MD
Cardiovascular Disease — Payments: $299,075
Cardiovascular Disease $299,075
Dr. William Maddox, M.d, M.D
Cardiovascular Disease — Payments: $172,753
Cardiovascular Disease $172,753
Dr. Gustavo Morales, Md, MD
Cardiovascular Disease — Payments: $124,880
Cardiovascular Disease $124,880
Thomas Cawthon, M.d, M.D
Cardiovascular Disease — Payments: $105,922
Cardiovascular Disease $105,922